Mucosal vaccines and technology

There is an urgent and unmet need to develop effective vaccines to reduce the global burden of infectious disease in both animals and humans, and in particular for the majority of pathogens that infect via mucosal sites. Here we summarise the impediments to developing mucosal vaccines and review the...

Descripción completa

Detalles Bibliográficos
Autores principales: Miquel‐Clopés, A., Bentley, E. G., Stewart, J. P., Carding, S. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Vaccines for Emerging Pathogens: from Research to the Clinic. Part 1. Series Editor: E Diane Williamson
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468177/
https://www.ncbi.nlm.nih.gov/pubmed/30963541
http://dx.doi.org/10.1111/cei.13285
_version_ 1783411379791724544
author Miquel‐Clopés, A.
Bentley, E. G.
Stewart, J. P.
Carding, S. R.
author_facet Miquel‐Clopés, A.
Bentley, E. G.
Stewart, J. P.
Carding, S. R.
author_sort Miquel‐Clopés, A.
collection PubMed
description There is an urgent and unmet need to develop effective vaccines to reduce the global burden of infectious disease in both animals and humans, and in particular for the majority of pathogens that infect via mucosal sites. Here we summarise the impediments to developing mucosal vaccines and review the new and emerging technologies aimed at overcoming the lack of effective vaccine delivery systems that is the major obstacle to developing new mucosal vaccines.
format Online
Article
Text
id pubmed-6468177
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64681772019-04-23 Mucosal vaccines and technology Miquel‐Clopés, A. Bentley, E. G. Stewart, J. P. Carding, S. R. Clin Exp Immunol Vaccines for Emerging Pathogens: from Research to the Clinic. Part 1. Series Editor: E Diane Williamson There is an urgent and unmet need to develop effective vaccines to reduce the global burden of infectious disease in both animals and humans, and in particular for the majority of pathogens that infect via mucosal sites. Here we summarise the impediments to developing mucosal vaccines and review the new and emerging technologies aimed at overcoming the lack of effective vaccine delivery systems that is the major obstacle to developing new mucosal vaccines. John Wiley and Sons Inc. 2019-04-08 2019-05 /pmc/articles/PMC6468177/ /pubmed/30963541 http://dx.doi.org/10.1111/cei.13285 Text en © 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Vaccines for Emerging Pathogens: from Research to the Clinic. Part 1. Series Editor: E Diane Williamson
Miquel‐Clopés, A.
Bentley, E. G.
Stewart, J. P.
Carding, S. R.
Mucosal vaccines and technology
title Mucosal vaccines and technology
title_full Mucosal vaccines and technology
title_fullStr Mucosal vaccines and technology
title_full_unstemmed Mucosal vaccines and technology
title_short Mucosal vaccines and technology
title_sort mucosal vaccines and technology
topic Vaccines for Emerging Pathogens: from Research to the Clinic. Part 1. Series Editor: E Diane Williamson
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468177/
https://www.ncbi.nlm.nih.gov/pubmed/30963541
http://dx.doi.org/10.1111/cei.13285
work_keys_str_mv AT miquelclopesa mucosalvaccinesandtechnology
AT bentleyeg mucosalvaccinesandtechnology
AT stewartjp mucosalvaccinesandtechnology
AT cardingsr mucosalvaccinesandtechnology

Ejemplares similares